THE ASSOCIATION OF LOW HEMOGLOBIN WITH THE RISK OF ADVERSE FETOMATERNAL OUTCOMES IN PATIENTS OF THALASSEMIA MINOR - A COHORT STUDY
DOI:
https://doi.org/10.71000/01y4eq27Keywords:
Anemia, , Beta-Thalassemia, Fetal Growth Retardation, Hemoglobinopathies, , Neonatal Outcomes, Obstetric Complications, Pregnancy, Pregnancy OutcomeAbstract
Background: Beta-thalassemia minor is generally considered a benign carrier state; however, emerging evidence suggests it may be associated with adverse maternal and neonatal outcomes, especially when compounded by anemia during pregnancy. Understanding this relationship is crucial for developing targeted antenatal care strategies in regions where thalassemia is prevalent.
Objective: To determine the association of low hemoglobin levels with the risk of adverse feto-maternal outcomes in pregnant women diagnosed with beta-thalassemia minor.
Methods: A prospective cohort study was conducted at Gynae C Unit, MTI-KTH Peshawar, over six months. A total of 158 pregnant women were enrolled, equally divided into exposed (beta-thalassemia minor with low Hb) and non-exposed (without thalassemia, normal Hb) groups using non-probability consecutive sampling. Data on demographics, hemoglobin levels, obstetric history, and adverse outcomes were recorded. Outcomes assessed included preterm birth, low birth weight, neonatal anemia, IUGR, maternal anemia, need for blood transfusion, and oligohydramnios. Data were analyzed using SPSS v23.0; relative risk (RR) and Chi-square tests were applied, with p < 0.05 considered statistically significant.
Results: Adverse outcomes were significantly more frequent in the exposed group. Preterm birth (24.1% vs. 10.1%), low birth weight (32.9% vs. 15.2%), neonatal anemia (26.6% vs. 11.4%), IUGR (21.5% vs. 8.9%), and maternal anemia (48.1% vs. 17.7%) were all more prevalent among women with beta-thalassemia minor. Blood transfusion and oligohydramnios were also notably higher in the exposed group.
Conclusion: Beta-thalassemia minor with low hemoglobin is significantly associated with adverse feto-maternal outcomes. These findings highlight the need for early screening and enhanced antenatal surveillance in affected pregnancies to mitigate risks.
References
Stanley AY, Wallace JB, Hernandez AM, Spell JL. Anemia in Pregnancy: Screening and Clinical Management Strategies. MCN Am J Matern Child Nurs. 2022;47(1):25-32.
Wu Y, Ji Y, Dai B, Guo F, Wu Y, He Z, et al. A case of hyperhaemolysis syndrome in a pregnant Chinese woman with β-thalassemia during perinatal transfusion. Transfus Med. 2021;31(1):24-9.
Thilakarathne S, Jayaweera UP, Uduweralla S, Pathinisekara S, Herath TU, Premawardhena A. Case-control study of maternal and fetal outcomes in beta thalassaemia trait during pregnancy. PLoS One. 2025;20(7):e0327132.
Singha K, Yamsri S, Chaibunruang A, Srivorakun H, Sanchaisuriya K, Fucharoen G, et al. Diagnostic value of fetal hemoglobin Bart's for evaluation of fetal α-thalassemia syndromes: application to prenatal characterization of fetal anemia caused by undiagnosed α-hemoglobinopathy. Orphanet J Rare Dis. 2022;17(1):45.
Vafaei H, Karimi S, Akbarzadeh Jahromi M, Asadi N, Kasraeian M. The effect of mother's β-thalassemia minor on placental histology and neonatal outcomes. J Matern Fetal Neonatal Med. 2022;35(10):1907-14.
Wu Y, Han L, Chen X, He J, Fan X, Dai J, et al. Effects of thalassemia on pregnancy outcomes of women with gestational diabetes mellitus. J Obstet Gynaecol Res. 2022;48(5):1132-40.
Musallam KM, Lombard L, Kistler KD, Arregui M, Gilroy KS, Chamberlain C, et al. Epidemiology of clinically significant forms of alpha- and beta-thalassemia: A global map of evidence and gaps. Am J Hematol. 2023;98(9):1436-51.
Fejzo M, Rocha N, Cimino I, Lockhart SM, Petry CJ, Kay RG, et al. GDF15 linked to maternal risk of nausea and vomiting during pregnancy. Nature. 2024;625(7996):760-7.
Amid A, Liu S, Babbs C, Higgs DR. Hemoglobin Bart's hydrops fetalis: charting the past and envisioning the future. Blood. 2024;144(8):822-33.
Anuruksuwan P, Sirilert S, Luewan S, Tongsong T. Impacts of β-thalassemia/hemoglobin E disease on pregnancy outcomes. Int J Gynaecol Obstet. 2024;166(1):360-7.
Chen N, Li Z, Huang Y, Xiao C, Shen X, Pan S, et al. Iron parameters in pregnant women with beta-thalassaemia minor combined with iron deficiency anaemia compared to pregnant women with iron deficiency anaemia alone demonstrate the safety of iron supplementation in beta-thalassaemia minor during pregnancy. Br J Haematol. 2022;196(2):390-6.
Charoenkwan P, Traisrisilp K, Sirichotiyakul S, Phusua A, Sanguansermsri T, Tongsong T. Noninvasive Prenatal Diagnosis of Beta-Thalassemia Disease by Using Digital PCR Analysis of Cell-Free Fetal DNA in Maternal Plasma. Fetal Diagn Ther. 2022;49(11-12):468-78.
Virot E, Thuret I, Jardel S, Herbrecht R, Lachenal F, Lionnet F, et al. Pregnancy outcome in women with transfused beta-thalassemia in France. Ann Hematol. 2022;101(2):289-96.
Ruangvutilert P, Phatihattakorn C, Yaiyiam C, Panchalee T. Pregnancy outcomes among women affected with thalassemia traits. Arch Gynecol Obstet. 2023;307(2):431-8.
Vlachodimitropoulou E, Mogharbel H, Kuo KHM, Hwang M, Ward R, Shehata N, et al. Pregnancy outcomes and iron status in β-thalassemia major and intermedia: a systematic review and meta-analysis. Blood Adv. 2024;8(3):746-57.
St-Georges J, Alnoman A, Badeghiesh A, Baghlaf H. Pregnancy, delivery, and neonatal outcomes among women with beta-thalassemia major: a population-based study of a large US database. Arch Gynecol Obstet. 2025;311(5):1343-9.
Adler A, Wainstock T, Sheiner E. Prenatal exposure to maternal β-thalassemia minor and the risk for long-term hematologic morbidity in the offspring: A population-based cohort study. Early Hum Dev. 2021;158:105397.
Cheng Y, Chen M, Ye J, Yang Q, Wang R, Liu S, et al. The prevalence and outcomes of α- and β-thalassemia among pregnant women in Hubei Province, Central China: An observational study. Medicine (Baltimore). 2022;101(9):e28790.
Nourollahpour Shiadeh M, Cassinerio E, Modarres M, Zareiyan A, Hamzehgardeshi Z, Behboodi Moghadam Z. Reproductive health issues in female patients with beta-thalassaemia major: a narrative literature review. J Obstet Gynaecol. 2020;40(7):902-11.
Zaccheddu E, Zappu A, Barella S, Clemente MG, Orecchia V, Pilia MP, et al. Unplanned pregnancy in women with beta-thalassaemia treated with luspatercept. Br J Haematol. 2024;204(6):2505-7.
Langer AL, Goggins BB, Esrick EB, Fell G, Berliner N, Economy KE. β-Thalassemia minor is associated with high rates of worsening anemia in pregnancy. Blood. 2025;145(6):648-51.
Vlachodimitropoulou A, Mogharbel H, Kuo KHM, Hwang M, Ward R, Shehata N, Malinowski AK. Pregnancy outcomes and iron status in β-thalassemia major and intermedia: a systematic review and meta-analysis. Blood Adv. 2024;8(3):746-7.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Aysha Rahman, Tayaba Mazhar , Qurat Ul Ain Zaman, Aleena Javed , Nayab Rawail, Zeenat Afridi (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
